Skip to main content

Advertisement

Table 3 Incidence of adverse events

From: Safety, tolerability, clinical, and joint structural outcomes of a single intra-articular injection of allogeneic mesenchymal precursor cells in patients following anterior cruciate ligament reconstruction: a controlled double-blind randomised trial

  MPC + HA (n = 11) HA alone (n = 6)
Total number of adverse events 94 39
 Non-serious, n (%) 92 (97.9) 39 (100.0)
 Serious, n (%) 2 (2.1)# 0 (0.0)
Adverse events by system organ class*, n (grade)
 Musculoskeletal and connective tissue disorders 11 (2) 6 (1)
 General disorders and administration site conditions 3 (2) 1 (1)
 Injury, poisoning, and procedural complications 2 (1) 2 (1)
 Infections and infestations 1 (1) 1 (1)
 Respiratory, thoracic, and mediastinal disorders 1 (1) 0
 Immune system disorders 2 (2) 1 (2)
  1. * Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE)
  2. # Non-treatment related